The Immunobiology of Psoriasis
Ongoing Developments in Biologic Therapy




Registration benefits include:
Access to CME/CE programs and certification
Free subscription to Biologic Bulletin newsletter
Reminders of new CME/CE activities
REGISTER NOW

This Web site is supported by an
unrestricted educational grant from
Genentech, Inc.
Biologic Therapy : References
References
  1. Gottlieb AB, Lifshitz B, Fu SM, et al. Expression of HLA-DR molecules by keratinocytes, and presence of Langerhans cells in the dermal infiltrate of active psoriatic plaques. J Exp Med. 1986;164:1013-1028.


  2. Gottlieb SL, Gilleaudeau P, Johnson R, et al. Response of psoriasis to a lymphocyte-selective toxin (DAB389IL-2) suggests a primary immune, but not keratinocyte, pathogenic basis. Nature Med. 1995;1:442-447.


  3. Gottlieb AB. Immunologic mechanisms in psoriasis. J Am Acad Dermatol. 1988;18:1376-1380.


  4. Krueger JG. Treating psoriasis with biologic agents. Science Med. 2002;May/June:150-161.


  5. Nickoloff BJ. The immunologic and genetic basis of psoriasis. Arch Dermatol. 1999;135:1104-1110.


  6. Dummer W, Joshi A, Beyer J, et al. Pharmacodynamic effects of subcutaneous (SC) administration of efalizumab (anti-CD11a). Presented at the 60th Annual Meeting of the American Academy of Dermatology; February 22-27, 2002; New Orleans, La. Poster #P547.


  7. Janeway CA, Travers P, Walport M, et al. Immunobiology. 5th ed. New York, NY: Garland Publishing; 2001.


  8. Krueger JG. The immunologic basis for the treatment of psoriasis with new biologic agents. J Am Acad Dermatol. 2002;46:1-23.


  9. Robert C, Kupper TS. Inflammatory skin diseases, T cells, and immune surveillance. N Engl J Med. 1999;341:1817-1828.


  10. Singri P, West DP, Gordon KB. Biologic therapy for psoriasis: the new therapeutic frontier. Arch Dermatol. 2002;138:657-663.
Previous